An update on ketamine and its two enantiomers as rapid-acting antidepressants

References

• Ebert B, Mikkelsen S, Thorkildsen C, et al. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol. 1997;333(1):99–104.
   PubMed Web of Science ®Google Scholar
• Domino EF. Taming the ketamine tiger. Anesthesiology. 2010;113(3):678–684.
   PubMed Web of Science ®Google Scholar
• Tyler MW, Yourish HB, Ionescu DF, et al. Classics in chemical neuroscience: ketamine. ACS Chem Neurosci. 2017;8(6):1122–1134.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res. 2018;7(F1000Faculty Rev):659.
   Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
   PubMed Web of Science ®Google Scholar
• Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–526.
   PubMed Web of Science ®Google Scholar
• Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127–1131.
   PubMed Web of Science ®Google Scholar
• Su TP, Chen MH, Li CT, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42(13):2482–2492.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–3580.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335.
   PubMed Web of Science ®Google Scholar
• Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336.
   PubMed Web of Science ®Google Scholar
• Albot CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–e309.
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Ca Z, Ds C, et al. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(1):537–547.
   PubMedGoogle Scholar
• Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–256.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826.
   PubMed Web of Science ®Google Scholar
• Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059–1077.
   PubMed Web of Science ®Google Scholar
• Loo CK, Gálvez V, O’keefe E, et al. Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56.
   PubMed Web of Science ®Google Scholar
• Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976.
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958–965.
   PubMed Web of Science ®Google Scholar
• Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16(9):2111–2117.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.
   PubMed Web of Science ®Google Scholar
• Zarate Jr CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–946.
   PubMed Web of Science ®Google Scholar
• Nugent AC, Diazgranados N, Carlson PJ, et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014;16(2):119–128.
   PubMed Web of Science ®Google Scholar
• Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067–1073.
   PubMed Web of Science ®Google Scholar
• Romeo B, Choucha W, Fossati P, et al. Meta-analysis of short-and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230(2):682–688.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry. 2013;74(10):e23–e24.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Toprak M, Turner MS, et al. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695–696.
   PubMed Web of Science ®Google Scholar
• Galea S, Nandi A, Vlahov D. The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev. 2005;27(1):78–91.
   PubMed Web of Science ®Google Scholar
• McGhee LL, Maani CV, Garza TH, et al. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma Acute Care Surg. 2008;64(2):S195–S199.
   Google Scholar
• Brachman RA, McGowan JC, Perusini JN, et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. 2016;79(9):776–786.
   PubMed Web of Science ®Google Scholar
• Mastrodonato A, Martinez R, Pavlova IP, et al. Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior. Biol Psychiatry. 2018;84(11):846-856.
   Web of Science ®Google Scholar
• Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688.
   PubMed Web of Science ®Google Scholar
• Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology (Berl). 2018;235(2):393–398.
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Flood P, et al. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder: a case report. J Clin Psychiatry. 2011;72(4):567.
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475.
   PubMed Web of Science ®Google Scholar
• Rodriguez CI, Wheaton M, Zwerling J, et al. Can exposure-based CBT extend IV ketamine’s effects in obsessive-compulsive disorder? An open-label trial. J Clin Psychiatry. 2016;7(3):408.
   Google Scholar
• Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964–970.
   PubMed Web of Science ®Google Scholar
• Glue P, Neehoff SM, Medlicott NJ, et al. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32(6):663–667.
   PubMed Web of Science ®Google Scholar
• Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325–333.
   PubMed Web of Science ®Google Scholar
• Shadli SM, Kawe T, Martin D, et al. Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. Int J Neuropsychopharmacol. 2018;8(1):717–724.
   Google Scholar
• Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012;72(11):e27–e28.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin Psychopharmacol Neurosci. 2012;10(1):59–60.
   PubMedGoogle Scholar
• Yang JJ, Wang N, Yang C, et al. Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry. 2015;77(3):e19–e20.
   PubMed Web of Science ®Google Scholar
• Kiraly DD, Horn SR, Van Dam NT, et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017;7(3):e1065.
   PubMedGoogle Scholar
• Park M, Newman LE, Gold PW, et al. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res. 2017;84:113–118.
   PubMed Web of Science ®Google Scholar
• Chen MH, Li CT, Lin WC, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res. 2018;269:207–211.
   PubMed Web of Science ®Google Scholar
• Kadriu B, Gold PW, Luckenbaugh DA, et al. Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Mol Psychiatry. 2018;23:1626–1631.
   PubMed Web of Science ®Google Scholar
• Zhang K, Ma M, Dong C, et al. Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol. 2018;21(11):1025-1030.
   Google Scholar
• Moaddel R, Shardell M, Khadeer M, et al. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology (Berl). 2018;235(10):3017–3030.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, R J L, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev Neurother. 2011;11(1):33–36.
   PubMed Web of Science ®Google Scholar
• Denk MC, Rewerts C, Holsboer F, et al. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry. 2011;168(7):751–752.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhou Z, Gao Z, et al. Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol Psychiatry. 2013;73(12):e35–e36.
   PubMed Web of Science ®Google Scholar
• Yang C, Ren Q, Qu Y, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83(1):18–28.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80(6):424–431.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Argolo FC, Araújo-de-Freitas L, et al. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat. 2017;13:1627–1632.
   PubMed Web of Science ®Google Scholar
• Bartova L, Papageorgiou K, Milenkovic I, et al. Rapid antidepressant effect of S-ketamine in schizophrenia. Eur Neuropsychopharmacol. 2018 Aug;28(8):980–982.
   PubMed Web of Science ®Google Scholar
• Morrison RL, Fedgchin M, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2018;235(4):1107–1119.
   PubMed Web of Science ®Google Scholar
• Van de Loo AJAE, Bervoets AC, Mooren L, et al. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study. Psychopharmacology (Berl). 2017;234(21):3175–3183.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630.
   PubMed Web of Science ®Google Scholar
• Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950–966.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Chawia JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459–1472.
   PubMed Web of Science ®Google Scholar
• Papadimitropoulou K, Vossen C, Karabis A, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin. 2017;33(4):701–711.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23(1):59–69.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li S, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361(1):9–16.
   PubMed Web of Science ®Google Scholar
• Yang C, Qu Y, Abe M, et al. (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry. 2017;82(5):e43–e44.
   PubMed Web of Science ®Google Scholar
• Yang C, Qu Y, Fujita Y, et al. Possible role of gut-microbiota in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry. 2017;7(12):1294.
   PubMedGoogle Scholar
• Yang C, Han M, Zhang JC, et al. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatric Res. 2016;239:281–283.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Kakiuchi T, Ohba H, et al. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):173–176.
   PubMed Web of Science ®Google Scholar
• Tian Z, Dong C, Fujita A, et al. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav. 2018;172:17–21.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci. 2014;12(1):72–73.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med. 2016;46(11):2449–2451.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets. 2016;20(11):1389–1392.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Detrimental side effects of repeated ketamine infusions in the brain. Am J Psychiatry. 2016;173(10):1044–1045.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Rapid-antidepressant activity of ketamine: beyond NMDA receptor. In: Hashimoto K, editor. The NMDA Receptors. New York: Humana Press; 2017. p. 69–82.
   Google Scholar
• White PF, Schüttler J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57(2):197–203.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7(1):25–38.
   PubMed Web of Science ®Google Scholar
• Yang C, Kobayashi S, Nakao K, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84(8):591–600.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Yang C. Is (S)-norketamine an alternative antidepressant for esketamine? Eur Arch Psychiatry Clin Neurosci. 2018 Jul 14. Doi:10.1007/s00406-018-0922-2.
   Google Scholar
• Singh I, Morgan C, Curran V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017;4(5):419–426.
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78.
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Hashimoto K. Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):177–182.
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Hashimoto K. Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21(1):84–88.
   PubMed Web of Science ®Google Scholar
• Zhang K, Fujita Y, Hashimoto K. Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model. Sci Rep. 2018;8(1):4007.
   PubMedGoogle Scholar
• Hashimoto K, Shirayama Y. What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine? Biol Psychiatry. 2018;84(1):e7–e8.
   PubMed Web of Science ®Google Scholar
• Chaki S. Is metabolism of (R)-ketamine essential for the antidepressant effects?. Int J Neuropsychopharmacol. 2018;21(2):154–156.
   PubMed Web of Science ®Google Scholar
• Yamaguchi JI, Toki H, Qu Y, et al. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology. 2018;43(9):1900–1907.
   PubMed Web of Science ®Google Scholar
• Chang L, Toki H, Qu Y, et al. No sex-specific differences in the acute antidepressant actions of (R)-ketamine in an inflammation model. Int J Neuropsychopharmacol. 2018;21(10):932–937.
   PubMedGoogle Scholar
• Zhang K, Toki H, Fujita Y, et al. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacology (Berl). 2018;235(11):3177–3185.
   PubMed Web of Science ®Google Scholar